CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States.

CKD Chronic kidney disease T2DM geographical variation prevalence spatial-temporal variation type 2 diabetes

Journal

Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300

Informations de publication

Date de publication:
Jan 2022
Historique:
entrez: 24 1 2022
pubmed: 25 1 2022
medline: 25 1 2022
Statut: epublish

Résumé

Regional variation in chronic kidney disease (CKD) prevalence in patients with or without type 2 diabetes mellitus (T2DM) has not been well characterized. Spatial and temporal comparative analysis. MarketScan databases were used to identify patients with CKD overall and subgroups of patients with CKD with and without T2DM in the United States. Spatial patterns in CKD prevalence based on year, regional clusters of CKD between years, and characteristics of patients in high-prevalence states. Geomapping was used to visualize the state-level data of CKD prevalence generated from 2013 to 2018. We used univariate local indicators of spatial association (LISA) to evaluate geographic differences in prevalence, differential LISA for changes in CKD prevalence over time, and the χ In univariate LISA, low-low clusters, in which a state has a low CKD prevalence and the surrounding states have a below-average CKD prevalence, were observed in the northwest region throughout the study period, regardless of the T2DM status, indicating a consistently low prevalence of CKD clustered in these areas. High-high clusters were observed, regardless of the T2DM status, in the southeast region in more recent years, suggesting an increased CKD prevalence in this region. Health care insurance enrollment might not have been representative of the United States; the estimates were based on claims data that likely underestimated the true prevalence. Geographic disparities in CKD prevalence appear increasingly magnified, with an increase in the southeastern region of the United States. This increase is especially problematic because patients with CKD in high-prevalence states experience a greater likelihood of chronic conditions than those in the rest of the United States.

Identifiants

pubmed: 35072048
doi: 10.1016/j.xkme.2021.09.003
pii: S2590-0595(21)00228-4
pmc: PMC8767132
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100385

Informations de copyright

© 2021 The Authors.

Références

JAMA Netw Open. 2020 Jul 1;3(7):e207932
pubmed: 32672828
BMC Nephrol. 2018 Mar 15;19(1):67
pubmed: 29544446
Int J Cardiol. 2013 Feb 20;163(2):206-11
pubmed: 22130225
Clin J Am Soc Nephrol. 2018 Mar 7;13(3):480-482
pubmed: 29242369
J Am Soc Nephrol. 2013 Feb;24(2):302-8
pubmed: 23362314
Med Care Res Rev. 2019 Feb;76(1):32-55
pubmed: 29148341
Am J Kidney Dis. 2010 Mar;55(3 Suppl 2):S23-33
pubmed: 20172445
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Int J Health Geogr. 2013 Mar 21;12:17
pubmed: 23518004
Pediatr Diabetes. 2019 Aug;20(5):523-529
pubmed: 30861241
BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154
pubmed: 27110365
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Am J Prev Med. 2011 Apr;40(4):434-9
pubmed: 21406277
Kidney Int. 2015 Oct;88(4):859-66
pubmed: 26221754
Kidney Int. 2017 Aug;92(2):388-396
pubmed: 28577854
PLoS One. 2018 Feb 9;13(2):e0192712
pubmed: 29425235
JAMA Netw Open. 2018 Nov 2;1(7):e184412
pubmed: 30646390
J Gen Intern Med. 2019 Mar;34(3):351-353
pubmed: 30367328
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
J Clin Med. 2018 Nov 28;7(12):
pubmed: 30486496

Auteurs

Xue Snow Feng (XS)

Bayer US LLC, Whippany, New Jersey.
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

Ryan Farej (R)

Bayer US LLC, Whippany, New Jersey.

Bonnie B Dean (BB)

Xcenda, Palm Harbor, Florida.

Fang Xia (F)

Bayer US LLC, Whippany, New Jersey.

Andrew Gaiser (A)

Xcenda, Palm Harbor, Florida.

Sheldon X Kong (SX)

Bayer US LLC, Whippany, New Jersey.

Jay Elliott (J)

Bayer US LLC, Whippany, New Jersey.

Stefanie Lindemann (S)

Bayer AG, Berlin, Germany.

Rakesh Singh (R)

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

Classifications MeSH